Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manoj Jagtiani

Interventional Pain Medicine Hays, KS Doctor of Osteopathy

NPI 1255829362 CMS profile 6325420

2220 Canterbury Dr, Hays, KS 67601

Open in the dashboard

General payments

$7,330

89 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manoj Jagtiani of Hays, KS is reported in the CMS Open Payments database as having received $7,330 across 89 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,609 19
2024 General $4,205 51
2023 General $1,003 13
2022 General $428 5
2019 General $86 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manoj Jagtiani
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Manoj Jagtiani were reported at $1,609. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Manoj Jagtiani Interventional Pain Medicine median Middle half National median
2019 $86 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $428 $605 $187–$1,924 $149
2023 $1,003 $671 $195–$1,915 $160
2024 $4,205 $684 $206–$1,837 $164
2025 $1,609 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nalu Medical, Inc. $1,937 19 payments
  2. Medtronic, Inc. $1,576 25 payments
  3. Nevro Corp. $1,217 15 payments
  4. SPR Therapeutics, Inc $800 9 payments
  5. Stryker Corporation $583 4 payments
  6. Painteq LLC $270 2 payments
  7. Saluda Medical Americas, Inc. $251 3 payments
  8. Abbott Laboratories $160 2 payments
  9. Vertos Medical, Inc. $155 2 payments
  10. Boston Scientific Corporation $147 2 payments
  11. Other $235 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,369 78 payments
  2. Travel and Lodging $2,961 11 payments
Products named General payments · program years 2019–2025
  1. Nalu Neurostimulation System $1,937 19 payments
  2. Senza $1,181 14 payments
  3. INTELLIS ADAPTIVESTIM $1,106 12 payments
  4. SPRINT PNS System $800 9 payments
  5. SPINEJACK $418 2 payments
  6. INCEPTIV $337 7 payments
  7. PAINTEQ $270 2 payments
  8. Evoke SCS $229 2 payments
  9. MILD DEVICE KIT Instruments $165 2 payments
  10. mild Device Kit Orthopedic $155 2 payments
  11. Other $589 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,057

Median for Pain Management: 951

Drug cost

$49,497

Median for Pain Management: $26,034

Branded share of claims

40.9%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 24 $17,097
Fentanyl Generic 28 $7,871
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 254 $7,628
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 131 $4,577
Oxycodone Hcl Generic 134 $3,390
Gabapentin Generic 149 $2,502
Lidocaine Generic 17 $1,919
Duloxetine Hcl Generic 44 $1,405
Pregabalin Generic 19 $1,069
Carisoprodol Generic 84 $424

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$224,943

Of which drugs: $3,042

Medicare patients

372

Average age 75

Services billed

14,349

227 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Depression 33%
Diabetes 30%
Osteoporosis 26%
Chronic kidney disease 24%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 54 11,501 $1,059

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $12
$12 — —
BOTOX
  • AbbVie, Inc. $12
$12 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $7
$7 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

89 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record